Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
AssigneeAlexion Pharmaceuticals, Inc.
InventorsKenji Fujita, Nishi Rampal, Wei-Jian Pan, Kaushik Patra
Life of this patent
Estimating the term…
Abstract
Provided are methods for clinical treatment of myasthenia gravis (MG) using an anti-C5 antibody or antigen binding fragment thereof.
Claims28
A method for treating a human patient with Myasthenia Gravis, the method comprising administering an antibody or antigen-binding fragment thereof to the patient, wherein the antibody or an antigen binding fragment thereof comprises CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:19, 18, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively, and wherein a treatment effect is observed at week 1 after initiation of treatment.
(canceled)
(canceled)
(canceled)
(canceled)
22-42. (canceled)
A method for treating a human patient with Myasthenia Gravis, the method comprising administering ravulizumab to a patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR), wherein the patient has a Myasthenia Gravis Activities of Daily Living (MG-ADL) score greater than or equal to 6, wherein the treatment results in the patient experiencing a clinically meaningful improvement (reduction) in the MG-ADL score after 26 weeks, and wherein a treatment effect is observed at week 1 after initiation of treatment.
A method for treating a human patient with Myasthenia Gravis, the method comprising administering ravulizumab to a patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR), wherein the patient has a Myasthenia Gravis Activities of Daily Living (MG-ADL) score greater than or equal to 6, wherein the treatment results in the patient experiencing a clinically meaningful improvement (reduction) in quantitative Myasthenia Gravis (QMG) score after 26 weeks, and wherein a treatment effect is observed at week 1 after initiation of treatment.
47-50. (canceled)
Dependencies are inferred from the claim text.